Close Menu

NEW YORK – Qiagen reported after the close of the market on Wednesday that its first quarter revenues grew 7 percent year over year, or up 9 percent at a constant exchange rate (CER).

For the three months ended March 31, Qiagen posted $372.1 million in revenues compared to $348.7 million in the year-ago period. It beat the analysts' average estimate of $344.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.